Skip to main content

Table 3 Adverse event incidence during the peri-anesthetization period

From: The efficacy and safety of ciprofol use for the induction of general anesthesia in patients undergoing gynecological surgery: a prospective randomized controlled study

Variable Ciprofol group
(n = 60)
Propofol group
(n = 60)
P-value
Intubation response, n(%)
 swallowing, 0 3(5%)  
 cough 0 1(1.67%)  
 body moving 0 2(3.33%)  
 tears 0 1(1.67%)  
 hypertension 4(6.67%) 2(3.33%)  
 hypotension 5(8.33%) 16(26.67%)  
 bradycardia 2(3.33%) 1(1.67%)  
 tachycardia 1(1.67%) 3(5%)  
 total 12(20%) 29(48.33%) 0.0019
Injection-site pain, n(%) 10(16.7%) 35(58.3%)  < 0.001
  1. Hypertension, hypotension, bradycardia and tachycardia were defined as occurred within 10 min after administration of the study drug were recorded; hypertension: an increase of 20% than baseline value; hypotension: an decrease of 20% than baseline; bradycardia: heart rates less than 55 beats/min; tachycardia: heart rates more than 100 beats/min; Injection-site pain: with a withdrawal response or a numeric rating scale value ≥ 3